MDA-MB-231 is a human breast cancer cell line widely used as an experimental model for triple-negative breast cancer, especially in studies of drug delivery, gene manipulation, and anti-cancer screening. It serves as a functional assay system to test nanocarrier uptake and biological effects, and the provided key fact notes superior cellular uptake compared with conventional techniques. In engineered contexts, i nos expression in MDA-MB-231 cells enables nitric oxide production, allowing researchers to probe immunometabolic and cytotoxic responses. Recent work also used this cell line to rank candidate PARP-1 inhibitors by predicted anti-cancer potential and to evaluate arginine-loaded MOF cytotoxicity and migration effects. Overall, MDA-MB-231 is a versatile TNBC platform for assessing delivery efficiency, therapeutic screening, and mechanistic tumor modulation.
Drug delivery and gene manipulation
- MDA-MB-231 breast cancer cells were used to evaluate the cellular uptake and functional effects of a nanocarrier system, with the model showing superior uptake versus conventional techniques. (PMID:41443126)
- The 2026 Colloids and Surfaces B: Biointerfaces study (PMID:41443126) used this cell line in the context of CRISPR-based MCP1 gene manipulation via MCM/Lys-Cys nanodevices.
- As an experimental cell model, MDA-MB-231 supported assessment of efficient gene delivery approaches in breast cancer. (PMID:41443126)
Triple-negative breast cancer and immunometabolic modulation
- MDA-MB-231 was engineered to express i nos, creating a triple-negative breast cancer model that produces nitric oxide for testing arginine-loaded MOF cytotoxicity. (PMID:42029068)
- The same 2026 Biomaterials Science study (PMID:42029068) used iNOS-transduced MDA-MB-231 cells to examine migration effects alongside antitumor activity.
- i nos activation in MDA-MB-231 cells enabled nitric oxide production in the engineered tumor cells, linking the model to immunometabolic modulation. (PMID:42029068)
Anti-cancer screening and target discovery
- MDA-MB-231 breast cancer cells were used to select the three best hits based on predicted anti-cancer potential in a fragment-based drug design and AI/ML workflow. (PMID:41724073)
- The 2026 Journal of Molecular Graphics and Modelling paper (PMID:41724073) applied this TNBC model to prioritize novel PARP-1 inhibitors.
- This cell line remains a standard platform for evaluating candidate anti-cancer compounds in triple-negative breast cancer. (PMID:41724073)